Keros Therapeutics (KROS) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Keros Therapeutics (KROS) over the past year, gaining 75.5% versus a loss of 28.4%. Over five years, SLGL leads with a -22.8% price change compared with -71.2% for KROS. Keros Therapeutics is the larger company by market cap ($230.8 million vs $230.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | SLGL |
|---|---|---|
| Share price | $11.64 | $70.34 |
| Market cap | $230.79M | $230.29M |
| 1-day change | +3.84% | -2.23% |
| YTD return | -44.94% | +70.73% |
| 1-year return | -28.37% | +75.52% |
| 5-year return | -71.25% | -22.85% |
| EPS (TTM) | $-3.22 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $97.97 |
| 52-week low | $9.69 | $28.81 |
| Distance from 52-week high | -48.38% | -28.20% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +70.36% | +116.80% |
| Average volume | 196.01K | 55.30K |
| Shares outstanding | 19.83M | 3.27M |
| Employees | 92 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed KROS by 103.9 percentage points over the past year.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
KROS vs SLGL FAQ
Which is bigger, Keros Therapeutics or Sol-Gel Technologies?
Keros Therapeutics (KROS) is larger, with a market capitalization of $230.79M compared with $230.29M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, KROS or SLGL?
SLGL returned +75.52% over the past 12 months, compared with -28.37% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.